Renal Impairment Study

Summary

Renal Impairment Study is a clinical trial^[1].

Key Facts

• Renal Impairment Study is in the country of Sweden^[2].
• Renal Impairment Study's instance of is recorded as clinical trial^[3].
• Renal Impairment Study's start time is recorded as +2009-03-31T00:00:00Z^[4].
• Renal Impairment Study's end time is recorded as +2010-02-28T00:00:00Z^[5].
• Renal Impairment Study's sponsor is recorded as AstraZeneca^[6].
• Renal Impairment Study's main subject is recorded as safety^[7].
• Renal Impairment Study's main subject is recorded as tolerability^[8].
• Renal Impairment Study's number of participants is recorded as {'unit': '1', 'amount': '+23'}^[9].
• Renal Impairment Study's title is recorded as A Phase I, Open Label, Non-randomized, Parallel Group, Pharmacokinetic Study in Subjects With Normal Renal Function, Moderate or Severe Renal Impairment Receiving a Single Dose of Oral 130 mg AZD3355^[10].
• Renal Impairment Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• Renal Impairment Study's ClinicalTrials.gov ID is recorded as NCT00863161^[12].
• Renal Impairment Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+70'}^[13].
• Renal Impairment Study's research intervention is recorded as lesogaberan^[14].
• Renal Impairment Study's clinical trial phase is recorded as phase I clinical trial^[15].
• Renal Impairment Study's research subject recruitment status is recorded as completed^[16].
• Renal Impairment Study's study type is recorded as interventional study^[17].